PWS European Blood Bank for Infants and Controls From 0 to 48 Months
Primary Purpose
Prader-Willi Syndrome
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
blood samples
Sponsored by
About this trial
This is an interventional basic science trial for Prader-Willi Syndrome
Eligibility Criteria
Inclusion Criteria (PWS infants cohort)
- Genetic diagnosis of Prader-Willi syndrome
Exclusion Criteria (PWS infants cohort)
- none
Inclusion Criteria (control group)
- children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
Exclusion Criteria (control group)
- children with endocrine disorder
Sites / Locations
- Unité d'Endocrinologie Pédiatrique / Université Catholique de Louvain
- Department of Pediatrics / Division of Endocrinology
- Department of Endocrinology / University Children's Hospital
- Department of Pediatrics / Division of Endocrinology / Erasmus University Medical Center / Sophia Children's Hospital Rotterdam
- Karolinska University Hospital
- Metabolic & Molecular Imaging Group / MRC Clinical Sciences Centre / Imperial College London / Hammersmith Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Infants with PWS
control group
Arm Description
Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
Outcomes
Primary Outcome Measures
Levels of hormones and neuropeptides
Measure of hormones and neuropeptides (ghrelin, insulin, leptin, pancreatic polypeptide, oxytocin, melatonin, orexins) involved in feeding and appetite regulation
Secondary Outcome Measures
Correlation between hormones and neuropeptides levels
study the correlation between ghrelin, insulin, leptin, pancreatic polypeptide, oxytocin, melatonin, orexins
Full Information
NCT ID
NCT02529085
First Posted
April 24, 2015
Last Updated
November 10, 2020
Sponsor
University Hospital, Toulouse
Collaborators
European Society for Paediatric Endocrinology
1. Study Identification
Unique Protocol Identification Number
NCT02529085
Brief Title
PWS European Blood Bank for Infants and Controls From 0 to 48 Months
Official Title
Study of Early Endocrine Profile in Infants With Prader-Willi Syndrome (PWS) in Order to Unravel the Switch From Early Feeding Difficulties to Obesity and Hyperphagia.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
March 2013 (Actual)
Primary Completion Date
June 1, 2017 (Actual)
Study Completion Date
June 1, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
Collaborators
European Society for Paediatric Endocrinology
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The present project aims to determine the underlying mechanisms for the switch from failure to thrive to excessive weight gain and hyperphagia with impaired satiety in PWS. The primary objective is to describe the evolution of circulating hormones involved in feeding and appetite regulation during the 4 first years of life. The secondary objective is to make this blood bank available for other research projects and particularly the investigation of hormones involved in hypogonadism.
Over the last ten years, the age at diagnosis in PWS has fallen significantly and the majority of cases is now diagnosed during the 1st trimester of life giving the possibility to collect precise clinical data and serum samples at early stages. The investigators of the project are involved in the care of patients with PWS and have a devoted clinic and an organized network in their country through clinical networks or patient associations.
Detailed Description
The investigators propose to perform a prospective multicentric study, both longitudinal (duration 30 months) and cross-sectional with implementation of a blood bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour. The cohort will include 200 infants from 3 to 48 months with PWS and 200 controls matched on age recruited in the 6 participating countries. The investigators make the assumption that 3 blood sampling will be necessary during the first year and 6 monthly sampling thereafter. For measuring hormones and neuropeptides (ghrelin, insulin, leptin, pancreatic polypeptide, oxytocin, cortisol, melatonin, orexin A, GLP-1 and PYY) involved in feeding and appetite regulation the investigators will use primarily multiplex microplates technics requiring 50-200µl of sample. Intragroup and intergroup comparisons will be performed in order to describe the evolution of each hormone with time and to compare data obtained in the PWS group with those obtained in the control group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prader-Willi Syndrome
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
215 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Infants with PWS
Arm Type
Experimental
Arm Description
Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
Arm Title
control group
Arm Type
Other
Arm Description
Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
Intervention Type
Other
Intervention Name(s)
blood samples
Intervention Description
blood samples for the bank
Primary Outcome Measure Information:
Title
Levels of hormones and neuropeptides
Description
Measure of hormones and neuropeptides (ghrelin, insulin, leptin, pancreatic polypeptide, oxytocin, melatonin, orexins) involved in feeding and appetite regulation
Time Frame
42 months
Secondary Outcome Measure Information:
Title
Correlation between hormones and neuropeptides levels
Description
study the correlation between ghrelin, insulin, leptin, pancreatic polypeptide, oxytocin, melatonin, orexins
Time Frame
42 months
10. Eligibility
Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria (PWS infants cohort)
Genetic diagnosis of Prader-Willi syndrome
Exclusion Criteria (PWS infants cohort)
none
Inclusion Criteria (control group)
children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
Exclusion Criteria (control group)
children with endocrine disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maithe TAUBER, MD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Unité d'Endocrinologie Pédiatrique / Université Catholique de Louvain
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Department of Pediatrics / Division of Endocrinology
City
Toulouse
State/Province
Haute-Garonne
ZIP/Postal Code
31000
Country
France
Facility Name
Department of Endocrinology / University Children's Hospital
City
Essen
Country
Germany
Facility Name
Department of Pediatrics / Division of Endocrinology / Erasmus University Medical Center / Sophia Children's Hospital Rotterdam
City
Rotterdam
ZIP/Postal Code
3015 GJ
Country
Netherlands
Facility Name
Karolinska University Hospital
City
Stockholm
Country
Sweden
Facility Name
Metabolic & Molecular Imaging Group / MRC Clinical Sciences Centre / Imperial College London / Hammersmith Hospital
City
London
ZIP/Postal Code
W12 0NN
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
24406482
Citation
Cadoudal T, Buleon M, Sengenes C, Diene G, Desneulin F, Molinas C, Eddiry S, Conte-Auriol F, Daviaud D, Martin PG, Bouloumie A, Salles JP, Tauber M, Valet P. Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment. Int J Obes (Lond). 2014 Sep;38(9):1234-40. doi: 10.1038/ijo.2014.3. Epub 2014 Jan 10.
Results Reference
background
PubMed Identifier
27146407
Citation
Beauloye V, Diene G, Kuppens R, Zech F, Winandy C, Molinas C, Faye S, Kieffer I, Beckers D, Nergardh R, Hauffa B, Derycke C, Delhanty P, Hokken-Koelega A, Tauber M. High unacylated ghrelin levels support the concept of anorexia in infants with prader-willi syndrome. Orphanet J Rare Dis. 2016 May 4;11(1):56. doi: 10.1186/s13023-016-0440-0.
Results Reference
derived
Learn more about this trial
PWS European Blood Bank for Infants and Controls From 0 to 48 Months
We'll reach out to this number within 24 hrs